Almirall's Study Shows Long-Term Benefits of Psoriasis Treatment Using WHO-5 Index

What's Happening?

Almirall has presented long-term results from the POSITIVE study, the first real-world dermatology study using the WHO-5 Well-Being Index as a primary endpoint, at the EADV 2025 Congress. The study assessed the treatment of moderate-to-severe psoriasis with tildrakizumab, showing sustained improvements in skin clearance, psychological well-being, and partner quality of life over two years. The study enrolled 785 patients across nine European countries, demonstrating tildrakizumab's effectiveness in holistic psoriasis management. Key findings include significant improvements in psychological well-being, skin clearance, and quality of life, with the treatment being well tolerated.

Why It's Important?

The POSITIVE study marks a paradigm shift in psoriasis treatment by focusing on holistic management, including psychological well-being and partner impact. This approach aligns with the WHO's call for integrated dermatology care, highlighting the importance of patient-centered treatment. The study's findings could influence future dermatological practices, emphasizing the need for comprehensive care that addresses both physical and psychological aspects of skin diseases. Almirall's leadership in advancing patient-centered dermatology could set new standards for treatment success and improve patient outcomes globally.

What's Next?

The POSITIVE study's results will be presented as a late-breaking abstract at the EADV 2025 Congress, highlighting its innovative approach. Almirall's commitment to advancing dermatology care continues with 44 scientific abstracts and expert-led symposia at the congress. The study supports the WHO's resolution on skin diseases as a global public health priority, potentially influencing the development of a Global Action Plan for dermatology care worldwide.